Vikram Sarabhai Space Centre director Dr K. Sivan said that efforts are on to put electric propelling system for satellites to enable them ...

The government is likely to commission a study soon to assess the impact of foreign direct investment in existing pharmaceutical companies

The Cabinet today deferred the consideration of proposals to relax foreign direct investment norms in the housing sector and to reduce the ...

The DIPP said current norms must lay down the foundation of what should be the nature of Indian drug companies in the long term.

The government is likely to finalise FDI policy with regard to existing drug companies ahead of the FIPB meeting on July 5.

With no let up in multinationals seeking nod to acquire stake in Indian pharma firms despite government putting norms to check it.

Department of Industrial Policy and Promotion seeks review of the policy barely months after it was cleared at the intervention of the PM.

IndUS Growth Partners is one of the four entities that Piramal has created to identify opportunities for M&A across sectors.

A Planning Commission expert group recommended that all M&As in the pharma industry should be cleared by CCI.

Amidst a debate whether FDI in pharma sector should be regulated ,Pranab Mukherjee said a decision on the issue would be taken.

It announced acquisition of IndiaReit Fund Advisors and IndiaReit Investment Managers for an aggregate of 225 crore.

The immediate trigger for the move was the acquisition of Ahmedabad-based Paras Pharmaceuticals by British consumer goods and healthcare fi...

The government has clarified that FDI in greenfield pharmaceutical projects will continue unhindered, but companies that receive government...

India has rejected a drug patent application of a US multi-national pharma company, paving way for easy access to an important life-saving ...

Takeovers by Abbot Labs, Bharti Airtel helped M & A's quadruple in the first half of this year from a year ago. Gainers, losers & recos | T...

US Food and Drug Administration's has given the approval to manufacture and market anti-bacterial drug oral Clarithromycin in multiple stre...

Dabur Pharma, the subsidiary of Dabur India, is set to acquire the cancer drug business of a South Asian pharmaceutical company.